Europe is currently grappling with an escalating public health challenge: chronic liver disease (CLD). A comprehensive new study published in The Lancet Regional Health – Europe reveals that millions of Europeans suffer from this silent yet severe condition, which is increasingly becoming a leading cause of premature morbidity and mortality across the continent. Spearheaded by the Barcelona Institute for Global Health (ISGlobal) and supported by the “la Caixa” Foundation, this collaborative work involving over 75 authors from 30 countries underscores the urgent need to reposition liver disease within broader health systems to prevent its devastating toll.
Chronic liver disease is no longer a niche hepatology issue—it has morphed into a multifactorial epidemic that cuts across socioeconomic strata, disproportionately impacting men and vulnerable populations. Recent epidemiological data place it as the second most significant cause, right after ischemic heart disease, in terms of years of working life lost in Europe. This emerging burden demands an integrated public health response that transcends traditional clinical specialties and health care silos.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is rapidly changing the face of liver pathology in Europe. Scientific evidence estimates that roughly one-third of the combined populations of the EU and the UK live with MASLD, positioning it as a primary driver of hepatic carcinogenesis. This metabolic liver disease represents a complex interplay of insulin resistance, obesity, dyslipidemia, and systemic inflammation, which underscores the necessity for its inclusion in metabolic syndrome-related health interventions.
Alcohol consumption remains a critical cofactor exacerbating CLD. Europe leads the globe in per capita alcohol intake, prevalence of binge drinking, and has among the lowest abstention rates worldwide. The synergistic effect of high alcohol exposure with metabolic risk factors propels the progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma at alarmingly high rates. Current estimates attribute approximately 40% of the yearly 287,000 premature liver-related deaths in Europe to alcohol, a figure likely underestimated due to underreporting and diagnostic challenges.
Liver disease exacts a steep toll on working-age adults, often causing fatalities decades earlier than other chronic conditions. Of particular concern is the underdiagnosis and undertreatment of viral hepatitis B and C, which together account for more than 85% of the nearly 57,000 deaths annually in the EU/EEA related to infectious diseases like HIV and tuberculosis. The chronic viral assault inflicts irreversible hepatic damage, increasing liver cancer risk and contributing significantly to regional disease burden.
The Lancet Series urges a transformative shift in public health strategies, advocating for liver disease to move from specialist hepatology settings into mainstream healthcare frameworks. Jeffrey V. Lazarus, Chair of the Series and a notable public health expert, emphasizes that current approaches insufficiently address the intertwined risk factors encompassing diet, alcohol, obesity, and sedentary lifestyle. Lazarus highlights the urgent imperative for primary care to incorporate liver fibrosis assessments alongside conventional metrics like blood pressure and cholesterol to enable early intervention.
The Series synthesizes the complex pathology of chronic liver disease through four interrelated themes: advancing diagnostic tools and care pathways, evaluating MASLD policy readiness, addressing alcohol-related liver conditions including MetALD, and reinforcing the agenda to eliminate viral hepatitis. This multifaceted approach enables the identification of synergistic interventions that tackle overlapping risk factors and address systemic inequities in liver health outcomes.
A key observation from the research is the pervasive stigma surrounding liver disease. Patient advocates involved in the study note that assumptions attributing liver disease purely to lifestyle choices lead to judgmental attitudes within healthcare and society, hindering effective care engagement. This stigma acts as a formidable barrier to timely diagnosis, adherence to treatment, and policy prioritization, propagating the under-recognition and ongoing public health neglect of liver disease.
Prominent voices within the Series advocate for collective government accountability rather than individual blame. Paul Brennan, co-Chair, stresses that liver diseases—MASLD, viral hepatitis, and alcohol-induced liver damage—predominantly affect socioeconomically marginalized groups. The Series delineates how evidence-based policies can reinforce earlier diagnostic precision, enhance preparedness of health systems, and create equitable care pathways to safeguard future generations against this mounting epidemic.
A salient concern addressed is the widespread underdiagnosis of chronic liver disease in primary and community settings. Millions remain unaware of their hepatic health status, permitting disease progression to irreversible stages marked by fibrosis, cirrhosis, and cancer. Automated, non-invasive liver fibrosis assessments integrated into routine care represent a critical opportunity for early detection, facilitating preemptive interventions aimed at halting disease advancement and forestalling premature mortality.
Among the Series’ pivotal recommendations is robust integration of liver health indicators into existing non-communicable disease (NCD) and cancer prevention programs. Coordinated policies targeting diabetes, obesity, alcohol consumption, cardiovascular health, physical inactivity, and nutritional factors could drastically reduce liver disease incidence. Furthermore, reinforcing surveillance mechanisms and facilitating access to effective treatment and harm reduction services are paramount to curtail the disease burden.
Implementing stringent alcohol control policies, including limiting commercial drivers of alcohol-related harm, forms a fundamental pillar in battling liver disease. The Series advocates for regulatory frameworks that minimize alcohol availability and consumption, thereby alleviating the combined impact of alcohol and metabolic dysfunction on liver disease progression. Parallel efforts must dismantle societal stigma and enhance healthcare accessibility, especially for underserved communities disproportionately affected by liver morbidity.
Ultimately, engaging the healthcare ecosystem from public health policymakers to primary care providers and patient advocacy groups is essential to reversing the trajectory of chronic liver disease in Europe. The Lancet Series underscores that postponing action until advanced disease diagnosis is the default path guarantees substantial morbidity and mortality. A comprehensive, integrated response that embraces early detection, prevention, and equitable care provision offers a realistic blueprint for ending the chronic liver disease public health threat in Europe.
The publication of this Series comes at a critical juncture, coinciding with the Global Think-tank on Steatotic Liver Disease’s Flagship Event hosted in Barcelona ahead of the European Association for the Study of the Liver (EASL) Congress. This confluence of scientific dialogue, policy advocacy, and patient engagement provides a powerful platform for catalyzing meaningful change in Europe’s approach to liver health, emphasizing the urgent need for coordinated, multidisciplinary solutions.
Subject of Research: People
Article Title: Ending the chronic liver disease public health threat in Europe
News Publication Date: 26-May-2026
Web References:
- The Lancet Regional Health – Europe series on chronic liver disease
- Global Think-tank on Steatotic Liver Disease Event
Keywords: chronic liver disease, metabolic dysfunction-associated steatotic liver disease, MASLD, alcohol-related liver disease, viral hepatitis, liver cancer, public health policy, early detection, liver fibrosis, Europe, health disparities, stigma, non-communicable diseases
